[go: up one dir, main page]

WO1997013748A1 - Sulfoxide derivatives of nitrogen-mustard and anticancer agent containing the same - Google Patents

Sulfoxide derivatives of nitrogen-mustard and anticancer agent containing the same Download PDF

Info

Publication number
WO1997013748A1
WO1997013748A1 PCT/KR1996/000173 KR9600173W WO9713748A1 WO 1997013748 A1 WO1997013748 A1 WO 1997013748A1 KR 9600173 W KR9600173 W KR 9600173W WO 9713748 A1 WO9713748 A1 WO 9713748A1
Authority
WO
WIPO (PCT)
Prior art keywords
chloroethyl
ethyl acetate
sulfoxide
bis
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR1996/000173
Other languages
French (fr)
Inventor
Jung Woo Kim
Chul-Hoon Kwon
Koo Hun Chung
Joon Kyum Kim
Jae Soo Shin
Kwan Kee Min
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chong Kun Dang Corp
Original Assignee
Chong Kun Dang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Corp filed Critical Chong Kun Dang Corp
Priority to AU73406/96A priority Critical patent/AU7340696A/en
Publication of WO1997013748A1 publication Critical patent/WO1997013748A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D219/00Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08Nitrogen atoms
    • C07D219/10Nitrogen atoms attached in position 9

Definitions

  • the present invention relates to sulfoxide derivatives of nitrogen-mustard which are represented by a general formula:
  • R 1 represents a hydrogen, or haloethyl
  • R 2 represents a lower alkyl or phenyl group substituted or non-substituted
  • X represents a halogen atom.
  • R 1 is a chloroethyl and X is a chlorine
  • R 2 does not represent methyl group; and pharmaceutically acceptable salts thereof, and their use as an anticancer agent.
  • nitrogen mustard forms aziridinium ion based upon the following reaction formula (A) , and combines with a DNA base by alkylation reaction to form the structure as illustrated in Example (B) .
  • nitrogen mustard can optionally attack any position of oxygen or nitrogen having lone pair electrons of DNA base molecule such as cytocine, guanine, thymine and adenine, it demonstrates a strong toxicity to cells. Further, with its non-selectivity property in distinguishing tumor cells from normal cells, nitrogen mustard shows a strong toxicity to normal cells.
  • melphalan is an antineoplastic agent having phenylalanine substituent on R group of nitrogen mustard.
  • the active form of this compound is delivered to the cells in a transport system of amino acid, which is indicated for the treatment of osteoma, ovarian cancer or mastocarcinoma by the therapy of a single agent or with concurrent administration.
  • some side effects associated with the overdose of melphalan are myelosuppression, gastrointestinal disturbances, and hypersensitivity; it has relatively low selectivity with negligible effects.
  • Chlorambusil with a similar structure to melphalan has been used for a long term treatment of leukemia but its high toxicity has led to some side-effects such as myelosuppression, nausea, hepatic disorder and hepatica tocixity.
  • the present inventors have endeavored to conduct the research and development of the compounds having strong activity and high selectivity to tumor cells thus, designing and synthesizing sulfoxide derived from nitrogen mustard, which is converted to the corresponding sulfide, a physiologically active metabolite as mentioned above, to complete this invention.
  • sulfoxide derivatives of nitrogen mustard do not form a bond with a DNA base by aziridine ring formation as mentioned above, so that it has no antineoplastic activity.
  • sulfone derivatives metabolites of the sulfoxide derivatives, have no antineoplastic activity in a normal state because of the same reason.
  • sulfoxide derivatives are metabolized to a sulfide derivatives under anaerobic (hypoxic) conditions, and the sulfide group readily go through aziridine ring formation, whereby showing very selective cytotoxicity.
  • the inner tumor cells, especially a solid cancer tissue has extremely hypoxic condition is well known, the sulfoxide derivatives having the above-described property are very useful for the treatment of solid cancers.
  • R, , R- and X are defined as above.
  • the compounds of the present invention can be synthesized by the use of known methods.
  • the compounds, wherein R 2 is lower alkyl or phenyl group substituted or non-substituted and R 1 is haloethyl can be prepared by reducing the nitro group at p-position to introduce an amino group; reacting with 2-chloroethanol or ethylene oxide/ acetone to introduce a hydroxyethyl group at N- position; reacting the product with halogenating agent; and then oxidizing the resultant sulfide group, as illustrated in Scheme I.
  • R 2 is lower alkyl or phenyl group substituted or non-substituted.
  • R 1 is H
  • R 2 is an aniline group having one or more lower alkyl group with halogen substituent at N- position
  • R 2 is an aniline group having one or more lower alkyl group with halogen substituent at N- position
  • R 2 is an aniline group having one or more lower alkyl group with halogen substituent at N- position
  • n and m are 0, 1, 2, but on the other hand n and m can not be 0 simultaneously
  • Figs. 1 - 4 are graphs of plotting the survival rate of V-79 cells under normal condition or hypoxic condition with regard to the concentration of medicines, when the compound of Example 5, 10, 14 or 17 is administered (Experimental Example 1) .
  • Figs. 5 and 6 show the result of the test for tumor inhibition in vivo (Experimental Example 2) .
  • the filtered product was suspended in boiling ethyl alcohol (60 ml) , and charcoal was added thereto. The suspension was heated under reflux for 30 min. The mixture was filtered hot, and the filtrate was quickly added to ice cold water (500 ml) causing the formation of a white precipitate. The mixture was then filtered and dried to give 10.1 g of crude white powder which contained 3 substances detected by UV after TLC operation.
  • This product was dissolved in hexane/EtOAc (4:1) (25 ml) and applied to a silica gel column (40 ⁇ m; 5 x 17 cm) packed dry. Then it was wet and eluted with the same solvent. The collected corresponding fractions were dried over anhydrous sodium sulfate and evaporated to give 8.13 g (yield: 85.6%) of pure compound as yellow oil.
  • Example 3 p-(n-Propylthio) -N.N-bis(2-hvdroxyethyl)aniline p-(n-Propylthio) aniline (8.12 g, 49 mmol) was added to a suspension of CaCO- (10.00 g, 100 mmol) in water (250 ml) .
  • Example 4 p-(n-Propylthio. -N.N-bis(2-chloroethyl) aniline p-(n-Propylthio) -N,N-bis(2-hydroxyethyl) aniline (3.80 g, 15 mmol) was dissolved in P0C1- (9.0 ml) with stirring. The solution was heated under reflux at 100°C in a water bath for 40 min, then the hot reaction mixture was cooled to room temperature. The mixture was extracted with ethyl acetate (4 x 100 ml) and washed with 10% sodium bicarbonate solution (3 x 200 ml) .
  • H 2 0 2 /trifluoroacetic acid prepared by adding 30% H 2 0 2 (8.6 ml) to trifluoroacetic acid (16.4 ml) , was added while stirring at 0°C. The reaction was allowed to proceed for 2h. The ice bath was removed and the reaction was allowed to continue for an additional 30 min. Trifluoroacetic acid was evaporated to give 0.78 g (yield : 74.3 %) of pure product as a light yellow solid.
  • Example 2 was repeated to give 11.65 g of white solid powder which contained 4 substances detected by UV after
  • Example 7 With the use of p-phenylthioaniline (50.0 mmol, 10.05 g) prepared in Example 7, the procedure of Example 3 was repeated to give 9.60 g of the crude product as a brown oil. The oil was applied to a silica gel column (40 ⁇ m, 5 x 17 cm) packed dry. Then it was wet and eluted with ethyl acetate / hexane (1:1) under a positive pressure (15 psi).
  • Example 8 the procedure of Example 4 was repeated to give 2.11 g of the crude product as a light brown viscous oil.
  • Example 10 p-(Phenylsulfinyl) -N.N-bis(2-chloroethyl) aniline
  • p-(phenylthio)-N,N-bis(2- chloroethyl)aniline (3.1 mmol, 1.00 g) prepared in Example 9
  • the procedure of Example 5 was repeated to give 0.84 g of the crude product as dark brown viscous oil.
  • the crude product was applied to a silica gel column (40 ⁇ m, 2.5 x 12.5 cm) packed dry. Then it was wet and eluted with ethyl acetate / hexane (3:1) under a positive pressure (15 psi).
  • the collected corresponding fractions were dried over anhydrous sodium sulfate and evaporated to obtain 0.71 g (yield: 68%) of the product as an light yellow crystalline product.
  • m.p. 122-124 °C
  • Example 12 4.4 ' -N . N . N ' . N ' -Tetrakis ( 2 - hydroxyethyl)dianiline sulfide
  • Example 13 4.4 ' -N . . N ' . N ' -Tetraki s ( 2 - chloroethyl)dianiline sulfide
  • 4 '-N,N,N' ,N'-tetrakis(2- hydroxyethyl)dianiline sulfide (7.4 mmol, 2.90 g) prepared in Example 12, the procedure of Example 4 was repeated to give 1.24 g of the crude product as a light brown oil. The crude product was applied to a silica gel column (40 ⁇ m, 5 x 12.5 cm) packed dry.
  • Example 14 4.5 ' -N . N . N ' . N ' -Te t r ak i s ( 2 - chloroethyl) dianiline sulfoxide
  • Example 13 With the use of 4, 4 '-N,N,N' ,N'-tetrakis (2- chloroethyl)dianiline sulfide (0.73 mmol, 0.35 g) prepared in Example 13, the procedure of Example 5 was repeated to give 0.31 g of the crude product as grey viscous oil.
  • the crude oil was diluted in ethyl acetate (2 ml) and applied to three preparative TLC plates, and was then eluted with ethyl acetate / hexane (3:2).
  • Example 15 4.4'-N.N'-bis(2-hvdroxyethyl. dianiline sulfide 4,4'-Diaminodiphenyl sulfide (5.00 g, 23.1 mmol) prepared in Example 11 and 2-chloroethanol (6.2 ml, 7.44 g, 92.4 mmol) were added to a suspension of CaC0 3 (4.10 g, 41.0 mmol) in water (150 ml) . The cloudy mixture was heated under reflux, while being protected from light for 24 h.
  • Example 17 4.4 -N.N -Bis(2-chloroethyl.dianiline sulfoxide
  • Example 18 4-[N.N-Bis(2-hydroxyethyl) 1amino-4 - nitrodiphenyl sulfide
  • Example 20 4 [N. N-Bis (2 -chloroethyl) laroino-4 '- nitrodiphenyl sulfoxide
  • Iron (19.14 g, 100 mesh) was activated by refluxing it with 1.5 ml of distilled water and 1 drop of concentrated hydrochloric acid for 0.5 h.
  • Ethanol (68.4 ml) and 4 - [N,N - bis (2 - chloroethyl) amino - 4' - nitrodiphenyl sulfoxide (13.67 g, 35.30 mmol) prepared in Example 20 were added into the mixture at 40 - 50 °C.
  • the reaction mixture was heated under reflux for 15 min.
  • Several drops of 10% NaOH was added to the reaction mixture to pH 8.
  • the hot reaction mixture was then filtered, and the residue was washed with ethanol and water.
  • Example 22 4-N.N-Bis(chloroethyl)amino-4'-(9-acridinyl. aminodiphenyl sulfide hydrochloride
  • Example 23 4- ⁇ N.N-Bis(chloroethyl) ]amino-4'-(9-acridinyl) aminodiphenyl sulfoxide hydrochloride
  • 4-[N,N-bis(2-chloroethyl) ]amino-4'- aminodiphenyl sulfoxide (1.00 g, 2.81 mmol) prepared in Example 21 and 9-chloroacridine (0.55 g, 2.57 mmol) prepared in Example 22, the procedure of Example 22 2) was repeated to give 1.3 g (yield: 88.45%) of the title compound as yellow solid, m.p. : 250-251 °C TLC : R f 0.81 (ethyl acetate) 1 H NMR (CDC1 3 / DMS0-d 6 1:4) 6 (ppm)
  • hypoxic set cells were gassed 10 min after injection of the drug, needles were pulled out and the sealed bottles were incubated for 3h in a normally aerated incubator. After drug exposure, the cells were washed twice with 5 ml sterile HBSS, and treated with 2.5% trypsin (Gibed® labs) for 2-3 min. Cells were collected by centrifugation, resuspended in 5 ml fresh solvent/or buffer and counted by trypan blue dye exclusion. Appropriate dilutions were made, and 500 cells were cultured in triplicate in a total of 10 ml medium. Dishes were incubated for 6-8 days to allow colony formation.
  • the sulfoxide derivatives according to the present invention have much lower cytotoxicity than the corresponding sulfide. It is found that the sulfoxides have rather higher cytotoxicity under hypoxic condition than under normal condition so that they have selective effects on a solid cancer having hypoxic condition as compared to the normal cells.
  • the B16 transformed cells cultured in vitro were treated with 0.25% trypsin, collected, washed with sterilized phosphate buffered saline (PBS) . And then the cell density was adjusted to 10 7 cells/ml. After 0.2 ml of cells (2 x 10 6 cells/ 0.2 ml/ mouse) were implanted into the subcutaneous tissue of the shoulder's upper part of BDF1 male mouse whose fur was previously eliminated, they were passaged in vivo per 14 days. B16 tumors were carefully isolated from the BDF1 male mouse tissue that had been passaged, necrosis cite was removed, and the weight of fresh tumor was measured.
  • PBS sterilized phosphate buffered saline
  • the mixture was ground by using a glass homogenizer to prepare a supernatant.
  • the supernatant was transplanted to a subcutaneous tissue of the shoulder's upper part of BDF1 male mouse (0.2 ml/ mouse) (0th day).
  • 45 animals having tumor tissue of 100 - 300 mm 3 volume were selected and divided into the experimental groups at random (6 animals per each group) .
  • the experimental compound(s) was administered into the abdominal cavity at the day 8 , 12, 16, and 20.
  • TGI tumor growth inhibition rate
  • Vt tumor volume of the administered group (mm 3 )
  • Vc tumor volume of the vehicle control group (mm 3 )
  • the growth of tumor can be inhibited by about 80% in case of administrating the sulfoxides of the present invention.
  • the tumor inhibition effect rises by 10% when using the compound of the present invention with the conventional compounds as compared to the case using only cyclo phosphamide (70%) , which whows the inhibition of growth of the solid cancer transplanted to mice.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

According to the present invention, are provided sulfoxide derivatives of nitrogen-mustard represented by general formula (I), wherein R1 represents a hydrogen, or haloethyl; R2 represents a lower alkyl or phenyl group substituted or non-substituted; and X represents a halogen atom. Provided that R1 is a chloroethyl and X is a chlorine, R2 does not represent methyl group; and an anticancer agent comprising the same as a prodrug. The sulfoxide derivatives according to the present invention convert to a sulfide in a hypoxic condition to show cytotoxicity, so that it is very useful as an anticancer agent selectively functions on a solid cancer which is in a hypoxic condition.

Description

TITLE OF INVENTION
SULFOXIDE DERIVATIVES OF NITROGEN-MUSTARD AND ANTICANCER
AGENT CONTAINING THE SAME
TECHNICAL FIELD
The present invention relates to sulfoxide derivatives of nitrogen-mustard which are represented by a general formula:
Figure imgf000003_0001
wherein, R1 represents a hydrogen, or haloethyl; R2 .represents a lower alkyl or phenyl group substituted or non-substituted; and X represents a halogen atom. Provided that R1 is a chloroethyl and X is a chlorine, R2 does not represent methyl group; and pharmaceutically acceptable salts thereof, and their use as an anticancer agent.
BACKGROUND ART
Despite improvements in chemotherapy for cancer in the past few decades, due care have been required in the clinical application of conventional anticancer agents in many cases due to their non-specific selectivity, including undesirable side effects. With their physiological properties (e.g., cellular heter ogeneity and inadequate blood flow in the local tumor site) , solid tumors have shown little responsiveness on chemotherapy and are also resistant to radiotherapy (Warren, 1978; Poste, 1986) . Now that said solid tumor cells have been reported to be in localized hypoxia, nutrient deprivation, and low pH (Kennedy et al., 1980), some selective-specific drugs on target sites have been suggested in consideration of said tumor's specific physiological and environmental factors (Denny and Wilson, 1986; Stratford et al., 1986; Sartorelli, 1988; Wilson et al., 1989a and 1989b; Denny et al., 1990) . In view of these situations, sulfoxide derivatives have been the remarkable prominent. Said compound is converted into sulfide, a physiologically active metabolite, by redox enzyme present in the mammal tissues, especially under hypoxic conditions.
In the meanwhile, nitrogen mustard forms aziridinium ion based upon the following reaction formula (A) , and combines with a DNA base by alkylation reaction to form the structure as illustrated in Example (B) . Since nitrogen mustard can optionally attack any position of oxygen or nitrogen having lone pair electrons of DNA base molecule such as cytocine, guanine, thymine and adenine, it demonstrates a strong toxicity to cells. Further, with its non-selectivity property in distinguishing tumor cells from normal cells, nitrogen mustard shows a strong toxicity to normal cells.
Figure imgf000004_0001
( N i t rogen mustard) ( Format i on of az i r i d i n i um sa l t !
( A l ky l at i on)
(A) [In the formula, X represents DNA base.]
Figure imgf000005_0001
In order to alleviate the toxicity of nitrogen mustard, attempts have been made to delocalize the lone pair electrons of nitrogen. Among these, melphalan is an antineoplastic agent having phenylalanine substituent on R group of nitrogen mustard. The active form of this compound is delivered to the cells in a transport system of amino acid, which is indicated for the treatment of osteoma, ovarian cancer or mastocarcinoma by the therapy of a single agent or with concurrent administration. However, some side effects associated with the overdose of melphalan are myelosuppression, gastrointestinal disturbances, and hypersensitivity; it has relatively low selectivity with negligible effects. Chlorambusil with a similar structure to melphalan has been used for a long term treatment of leukemia but its high toxicity has led to some side-effects such as myelosuppression, nausea, hepatic disorder and hepatica tocixity.
Figure imgf000005_0002
me i pnaIan chlorambusi
To be free from the aforementioned disadvantages the conventional arts face, the present inventors have endeavored to conduct the research and development of the compounds having strong activity and high selectivity to tumor cells thus, designing and synthesizing sulfoxide derived from nitrogen mustard, which is converted to the corresponding sulfide, a physiologically active metabolite as mentioned above, to complete this invention.
In general, sulfoxide derivatives of nitrogen mustard do not form a bond with a DNA base by aziridine ring formation as mentioned above, so that it has no antineoplastic activity. Also, sulfone derivatives, metabolites of the sulfoxide derivatives, have no antineoplastic activity in a normal state because of the same reason. However, sulfoxide derivatives are metabolized to a sulfide derivatives under anaerobic (hypoxic) conditions, and the sulfide group readily go through aziridine ring formation, whereby showing very selective cytotoxicity. As the fact that the inner tumor cells, especially a solid cancer tissue has extremely hypoxic condition is well known, the sulfoxide derivatives having the above-described property are very useful for the treatment of solid cancers.
R
Figure imgf000006_0001
l f ox i de( no act i v i ty) sulfone (no act ivi ty,
[o: [ H ]
====> aziridinium ring Tormaiion sul f iύe (high act IVI ty) In 1992, p-(methylsulfinyl)phenyl nitrogen mustard as a sulfoxide prodrug of an anti-cancer agent, which is converted to a sulfide, under hypoxic conditions, designed to specifically attack the tumor cells, has been developed by the inventor of the present invention. However, the compound has insufficient cytotoxicity (specific action to the tumor cells) , so that an anticancer agent having more selectivity and more excellent effect.
DISCLOSURE OF THE INVENTION
As a result of intensive study to develop the prodrug of an anti-cancer medicine having excellent selectivity to tumor cells, the present inventor unexpectedly found that the sulfoxide derivatives of nitrogen mustard represented by general formula (I) can fulfill these requirements.
Figure imgf000007_0001
(I)
In the formula, R, , R- and X are defined as above.
Among the compounds, p- (n-propylsulf inyl) -N,N-bis(2- chloroethyl) aniline, p- (phenylsulf inyl ) -N,N-bis(2- chloroethyl) aniline, 4,4'-N,N,N' ,N'-tetrakis(2- chloroethyl) dianiline sulfoxide, 4 , 4 ' -N, N' -bis (2- chloroethy 1 ) dianil ine sulfoxide and 4-N,N- bis (chloroethyl) amino-4 ' - (9-acridinyl) aminodi phenyl sulfoxide are mentioned as desirable compounds. The compounds of the present invention can be synthesized by the use of known methods. For example, the compounds, wherein R2 is lower alkyl or phenyl group substituted or non-substituted and R1 is haloethyl, can be prepared by reducing the nitro group at p-position to introduce an amino group; reacting with 2-chloroethanol or ethylene oxide/ acetone to introduce a hydroxyethyl group at N- position; reacting the product with halogenating agent; and then oxidizing the resultant sulfide group, as illustrated in Scheme I.
Scheme
Figure imgf000008_0001
(In the formula, R2 is lower alkyl or phenyl group substituted or non-substituted.) The compounds, wherein R2 is lower alkyl or phenyl group substituted or non-substituted and R1 is H, can be systhesized by concentration control of C1CH-CH-.OH used at the second step of the above scheme I.
The compounds wherein R2 is an aniline group having one or more lower alkyl group with halogen substituent at N- position can be obtained by firstly preparing 4,4'- dia inodiphenyl sulfide; introducing one or more hydroxyethyl group to the amino group of the compound; halogenating the introduced hydroxy group; and oxidizing the sulfide group, as illustrated in Scheme II.
Figure imgf000009_0002
(In the formula, n and m are 0, 1, 2, but on the other hand n and m can not be 0 simultaneously)
Depending upon the features of the substituent
20 included in R2 group, various derivatives may be synthesized as shown, for example, in the following reaction schemes :
5 Scheme
Figure imgf000009_0001
5
Figure imgf000010_0001
BRIEF DESCRIPTION OF THE DRAWINGS
Figs. 1 - 4 are graphs of plotting the survival rate of V-79 cells under normal condition or hypoxic condition with regard to the concentration of medicines, when the compound of Example 5, 10, 14 or 17 is administered (Experimental Example 1) .
Figs. 5 and 6 show the result of the test for tumor inhibition in vivo (Experimental Example 2) .
BEST MODE FOR CARRYING OUT THE INVENTION
Here-in-after, the present invention will be described in detail by referring to the following Examples and Experimental Examples. However, it should be noted that the present invention is not restricted to these Examples.
Example 1 : p-(n-Propylthio)nitrobenzene
1-Bromopropane (7.5 ml, 8.24 g, 83 mmol) was added with stirring to a solution of p-nitrothiophenol (10.70 g, 69 mmol) in 50 ml of ethyl alcohol. To the clear orange- color solution, 40% NaOH solution (6.9 ml, 69 mmol) was added and the solution was heated under reflux for 40 min. The clear orange solution was cooled, and ice water was added thereto. The mixture was extracted with methylene chloride (4 x 100 ml) . The combined organic layer was dried over anhydrous Na2S04 and evaporated to give 14.92 g of brown oil which contained 4 substances detected by UV after TLC operation. This brown oil was applied to a silica gel column (40 μm; 5 x 17 cm) packed dry. Then it was wet and eluted with hexane/EtOAc (4:1) under a positive pressure (15 psi) . The corresponding fractions were collected, and the solvent was removed by evaporation to give 11.20 g (yield: 86.3%) of pure compound as orange crystalline solid. m.p. = 102-103 °C
TLC : Rf = 0.71 in hexane/EtOAc (4:1)
1H NMR (CDC1-) <_ (ppm)
7.32-7.60 & 8.15-8.44 (dd, 4H, -C6H4~) , 3.01-3.33 (t, 2H, -CH2S-) , 1.66-2.19 (m, 2H, CH2) ,
1.08-1.50 (t, 3H, CH3)
Example 2 : p-(n-Propylthio)aniline
To a boiling suspension of p-(n-propylthio)nitro benzene (11.20 g, 67 mmol) suspended in a solution of 37% HCl (35 ml) and water (30 ml), tin turnings (11.0 g) were added upon which the suspension became a clear light brown solution. The solution was heated under reflux with vigorous stirring for 15 min. Activated charcoal (0.1 g) was added and the mixture was allowed to continue refluxing for an additional 15 min. The mixture was filtered hot and the filtrate was cooled and diluted with cold water (100 ml) . Aqueous NaOH (40%) was added till the mixture became strongly alkaline. The resulting gray product was filtered. The filtered product was suspended in boiling ethyl alcohol (60 ml) , and charcoal was added thereto. The suspension was heated under reflux for 30 min. The mixture was filtered hot, and the filtrate was quickly added to ice cold water (500 ml) causing the formation of a white precipitate. The mixture was then filtered and dried to give 10.1 g of crude white powder which contained 3 substances detected by UV after TLC operation. This product was dissolved in hexane/EtOAc (4:1) (25 ml) and applied to a silica gel column (40 μm; 5 x 17 cm) packed dry. Then it was wet and eluted with the same solvent. The collected corresponding fractions were dried over anhydrous sodium sulfate and evaporated to give 8.13 g (yield: 85.6%) of pure compound as yellow oil.
TLC : Rf = 0.37 [hexane/ ethyl acetate (4:1)] H NMR (CDClj) δ (ppm)
6.55-6.82 & 7.19-7.50 (dd, 4H, -C4H6-) , 3.58 (s, 2H, NH2) , 2.68-3.08 (t, 2H, CH-.S-) , 1.32-1.93 (m, 2H, CH2) , 0.85-1.30 (t, 3H, CH3)
Example 3 : p-(n-Propylthio) -N.N-bis(2-hvdroxyethyl)aniline p-(n-Propylthio) aniline (8.12 g, 49 mmol) was added to a suspension of CaCO- (10.00 g, 100 mmol) in water (250 ml) .
The cloudy mixture was heated under reflux with vigorous stirring, protected from light, for 24 h. An additional four equivalents of 2-chloroethanol (14.3 ml, 196 mmol) and CaCO- (10.00 g, 100 mmol) were added in two(2) equivalent portions over the following 48 h. The reaction mixture was then cooled, pH (5.1) adjusted to 7.0 with 10% aqueous NaOH, and the mixture was extracted with EtOAc (4 x 200 ml) . The combined organic layer was dried over anhydrous sodium sulfate and evaporated to give 8.18 g of a brown oil. The crude material was applied to a silica gel column (40 μm, 5 x 17 cm) packed dry. Then it was wet and eluted with EtOAc/hexane (2:1) under a positive pressure (15 psi) . The collected corresponding fractions were dried over anhydrous sodium sulfate and evaporated to give 3.80 g (yield: 30.6%) of the product as a pale brown oil. TLC : Rf = 0.46 [hexane/ ethyl acetate (1:3)] 1H NMR (CDClj) (ppm) 6.38-6.73 & 7.05-7.40 (dd, 4H, -C6H4~) , 3.15-3.94
[m, 10H, -N(CH2CH2OH)2] , 3.14-2.95 (t, 2H, CH-S- ), 1.32-1.68 (m, 2H, -CH2-) , 0.73-1.12 (t, 3H, CH3).
Example 4 : p-(n-Propylthio. -N.N-bis(2-chloroethyl) aniline p-(n-Propylthio) -N,N-bis(2-hydroxyethyl) aniline (3.80 g, 15 mmol) was dissolved in P0C1- (9.0 ml) with stirring. The solution was heated under reflux at 100°C in a water bath for 40 min, then the hot reaction mixture was cooled to room temperature. The mixture was extracted with ethyl acetate (4 x 100 ml) and washed with 10% sodium bicarbonate solution (3 x 200 ml) . The combined organic layer was dried over anhydrous sodium sulfate and evaporated to give 3.23 g of the product as a brown oil. TLC : Rf = 0.84 [hexane/ ethyl acetate (2:1)] 1H NMR (CDClj) <S (ppm)
6.48-6.73 & 7.07-7.46 (dd, 4H, -C6H4-) , 3.32-3.75 [m, 8H, -N(CH2CH2C1)2] , 2.58-2.89 (t, 2H, CH-S-) , 1.32-1.82 (m, 2H, -CH2~) , 0.76-1.15 (t, 3H, CH3-)
Elemental analysis C13H19C12NS
Calcd . : C , 53 . 42 ; H , 6 . 55 ; N , 4 . 79 ; S , 10 . 97 ; Cl ,
24.26 Found : C, 53.44; H, 6.53; N, 4.81; S, 10.87; Cl , 24.18 Example 5 : p-(n-Propylsulfinyl) -N.N-bis ( 2-chloroethyl) aniline
To a solution of p-(n-propylthio)-N,N-bis(2- chloroethyl)aniline (1.00 g, 3.4 mmol) in trifluoroacetic acid (5 ml), H202/trifluoroacetic acid (1.0 ml, 1 equivalent), prepared by adding 30% H202 (8.6 ml) to trifluoroacetic acid (16.4 ml) , was added while stirring at 0°C. The reaction was allowed to proceed for 2h. The ice bath was removed and the reaction was allowed to continue for an additional 30 min. Trifluoroacetic acid was evaporated to give 0.78 g (yield : 74.3 %) of pure product as a light yellow solid.
TLC : Rf = 0.41 [hexane/ ethyl acetate (1:3)] H NMR (CDC1-) <_ (ppm) 6.30-6.61 & 6.98-7.39 (dd, 4H, -CfiH4-) , 3.38-3.79
[m, 8H, -N(CH2CH2C1)2] , 2.71-3.00 (t, 2H, CH-SO- ), 1.40-1.84 (m, 2H, -CH2~) , 0.78-1.15 (t, 3H, CH--) Elemental analysis C13H19C12NS0 Calcd. : C, 50.65; H, 6.21; N, 4.54; S, 10.40;
Cl, 23.00 Found : C, 50.39; H, 6.09; N, 4.63; S, 10.47; Cl, 22.85
Example 6 : p-(4-nitrophenyl) henyl sulfide
Thiophenol (3.0 ml, 4.73 g, 43 mmol) was added to a boiling solution of l-bromo-4-nitrobenzene (8.70 g, 43 mmol) in ethyl alcohol (50 ml). Aqueous NaOH (40%) (3.0 ml, 43 mmol) was then added drop-wise to the solution and the solution heated under reflux for 1 h. The solution was cooled, diluted with water (200 ml) , and then extracted with CH-C1-. (4 x 150 ml) . The combined organic layer was washed with 10% NaOH, dried over anhydrous Na2S04 and evaporated to give 8.63 g (85% yield) of the product as chro atographically pure yellow solid. m . p . : 89 - 91 °C
TLC : Rf = 0.69 [hexane/ ethyl acetate (20:1)]
1H NMR (CDC13) δ (ppm)
7.41 (s, 5H, C6H5S) , 7.02-7.73 (dd, 4H, C6H4N02~) IR (Nujol, cm"1)
3030, 1600-1500 (C&H4) , 1530, 1350 (N02)
Example 7 : p-Phenylthioaniline
With the use of p-(4-nitrophenyl)phenyl sulfide (59.7 mmol, 13.80 g) prepared in Example 6, the procedure of
Example 2 was repeated to give 11.65 g of white solid powder which contained 4 substances detected by UV after
TLC operation. The solid was dissolved in 30 ml of hexane/EtOAc (3:1), applied to a silica gel column (40 μm; 5 x 17 cm) packed dry. Then it was wet and eluted with hexane/EtOAc (3:1) at a positive pressure (15 psi) . The collected corresponding fractions were evaporated to obtain
10.23 g (yield: 85.3%) of the product as while solid crystalline product. m.p. : 91-93 °C
TLC : Rf = 0 . 48 [ hexane/ ethyl acetate ( 3 : 1 ) ] 1H NMR ( CDC13) (ppm)
7 . 13 ( s , 5H , C6H5S ) , 6 . 68 - 7 . 50 (dd , 4H , -C6H4NH2)
Example 8 : p-(Phenylthio) -N.N-bis(2-hydroxyethyl)aniline
With the use of p-phenylthioaniline (50.0 mmol, 10.05 g) prepared in Example 7, the procedure of Example 3 was repeated to give 9.60 g of the crude product as a brown oil. The oil was applied to a silica gel column (40 μm, 5 x 17 cm) packed dry. Then it was wet and eluted with ethyl acetate / hexane (1:1) under a positive pressure (15 psi).
The collected corresponding fractions were dried over anhydrous sodium sulfate and evaporated to obtain 2.26 g (yield: 16.2%) of the product as brown oil. TLC : Rf = 0 . 25 [hexane/ ethyl acetate ( 1 : 2 ) ] H NMR ( CDC13) δ (ppm)
7 . 19 (s , 5H , C6H5S-) , 6 . 52-6 . 77 (dd , 4H , C6H4~ ) , 3 . 26-4 . 00 [m, 10H , N (CH2CH-.OH) 2 ]
Example 9 : p-(Phenylthio)-N.N-bis(2-chloroethyl_ aniline
With the use of p-(phenylthio) -N,N-bis(2- hydroxyethyl)aniline (7.82 mmol, 2.26 g) prepared in
Example 8, the procedure of Example 4 was repeated to give 2.11 g of the crude product as a light brown viscous oil.
The crude product was applied to a silica gel column (40 μm, 2.5 x 12.5 cm) packed dry. Then it was wet and eluted with ethyl acetate / hexane (1:4) under a positive pressure
(15 psi) . The collected corresponding fractions were dried over anhydrous sodium sulfate and evaporated to obtain 2.03 g (yield: 80%) of the product as light brown oil.
TLC : Rf = 0.69 [hexane/ ethyl acetate (4:1)], UV quenching and NBP positive 1H NMR (CDC13) <S (ppm) 7.11 (s, 5H, C6H5S-) , 6.40-7.48 (dd, 4H, C6H4N-) ,
3.32-3.78 [m, 8H, N(CH-CH2C1)2] Elemental analysis C16H17C1-NS
Calcd. : C, 58.90; H, 5.25; N, 4.29; S, 9.83; Cl, 21.73 Found : C, 58.77; H, 5.16; N, 4.23; S, 9.72;
Cl, 21.70
Example 10 : p-(Phenylsulfinyl) -N.N-bis(2-chloroethyl) aniline With the use of p-(phenylthio)-N,N-bis(2- chloroethyl)aniline (3.1 mmol, 1.00 g) prepared in Example 9, the procedure of Example 5 was repeated to give 0.84 g of the crude product as dark brown viscous oil. The crude product was applied to a silica gel column (40 μm, 2.5 x 12.5 cm) packed dry. Then it was wet and eluted with ethyl acetate / hexane (3:1) under a positive pressure (15 psi). The collected corresponding fractions were dried over anhydrous sodium sulfate and evaporated to obtain 0.71 g (yield: 68%) of the product as an light yellow crystalline product. m.p. : 122-124 °C
TLC : Rf = 0.68 [hexane/ ethyl acetate (1:3)]
1H NMR (CDC13) δ (ppm)
7.20 (s, 5H, C6H5S-) , 6.51-7.59 (dd, 4H, -C6H_N- ) , 3.36-3.77 [m, 8H, N(CH2CH-C1) 2]
Elemental analysis C16H17C12NS0
Calcd. : C, 56.15; H, 5.01; N, 4.09; S, 9.37;
Cl, 20.72 Found : C, 56.20; H, 5.03; N, 4.04; S, 9.45; Cl, 20.64
Example 11 : 4 ,4 '-Diaminodiphenyl sulfide
4-Amino-4'-nitrodiphenyl sulfide (10.00 g, 40 mmol) was suspended in a solution of cone. HCl (37%) (26.5 ml) and water (25 ml) , and the light yellow suspension was heated to 100°C. To the boiling suspension, thus obtained tin turnings (9.00 g) were added to form a clear dark yellow solution. Additional HCl (2.0 ml) and tin turnings (1.00 g) were added and the solution was allowed to boil under reflux for 15 min. Activated charcoal (0.1 g) was added to the mixture and the reaction was allowed to boil for an additional 10 min. The mixture was filtered hot and the filtrate was allowed to cool. To the cooled filtrate, water (150 ml) and 40% aqueous NaOH was added till the solution became strongly alkaline (pH 12-13) and the resulting precipitate was filtered. The filtered grey solid product was dissolved in boiling alcohol (60 ml) and heated with activated charcoal (0.25 g) under reflux for 30 min. The mixture was filtered hot and the hot filtrate was added to ice cold water (500 ml) which resulted in the precipitation of a white solid. The solid was filtered and dried to give 6.51 g (yield: 71.2 %) of the product as a white crystalline solid, m.p. : 104 - 107 °C TLC : Rf = 0.50 [hexane / ethyl acetate (1:1)]
Example 12 : 4.4 ' -N . N . N ' . N ' -Tetrakis ( 2 - hydroxyethyl)dianiline sulfide
4,4'-Diaminodiphenyl sulfide (6.50 g, 30 mmol) and 2- chloroethanol (16.1 ml, 19.32 g, 240 mmol) were added to a suspension of CaC03 (12.00 g, 120 mmol) in water (200 ml). The cloudy mixture was heated under reflux with vigorous stirring, while being protected from light for 24 h. An additional 4 equivalents of 2-chloroethanol (8.0 ml, 9.66 g, 120 mmol) and CaC03 (6.00 g, 60 mmol) were added and the reaction was allowed to continue for 24 h. The reaction mixture was then cooled, and the pH (2.6) was adjusted to 7.0 with 10% NaOH. The mixture was then extracted with ethyl acetate (4 x 100 ml) . The combined organic layer was dried over anhydrous sodium sulfate and evaporated to give 6.60 g of a dark brown viscous oil which contained 5 substances detected by UV after TLC operation. The crude oil was then applied to a silica gel column (40 μm, 5 x 15 cm) packed dry. Then it was wet and eluted with ethyl acetate under a positive pressure (15 psi) . The collected corresponding fractions were dried over anhydrous sodium sulfate and evaporated to obtain 3.15 g (yield: 26.8%) of the product as clear viscous oil.
TLC : Rf = 0.30 (ethyl acetate) 1H NMR (CDC13) δ (ppm)
6.32-6.72 & 6.90-7.30 [dd, 8H, S(C6H4)2], 3.16-3.68 [m, 20H, N(CH-.CH-.0H)-]
Example 13 : 4.4 ' -N . . N ' . N ' -Tetraki s ( 2 - chloroethyl)dianiline sulfide With the use of 4,4 '-N,N,N' ,N'-tetrakis(2- hydroxyethyl)dianiline sulfide (7.4 mmol, 2.90 g) prepared in Example 12, the procedure of Example 4 was repeated to give 1.24 g of the crude product as a light brown oil. The crude product was applied to a silica gel column (40 μm, 5 x 12.5 cm) packed dry. Then it was wet and eluted with hexane / ethyl acetate (5:1) under a positive pressure (15 psi) . The collected corresponding fractions were dried over anhydrous sodium sulfate and evaporated to obtain 0.82 g (yield: 23.7%) of the product as yellow oil.
TLC : Rf = 0.51 [hexane/ ethyl acetate (5:1)], UV quenching and NBP positive 1H NMR (CDC13) δ (ppm)
6.48-6.80 & 7.10-7.51 [dd, 8H, S(C6H4)2], 3.46-3.89 [m, 16H, N(CH-.CH2C1)2]
Elemental analysis C20H24C14N2S
Calcd. : C, 51.52; H, 5.19; N, 6.01; S, 6.88;
Cl, 30.41 Found : C, 51.43; H, 5.16; N, 5.99; S, 6.92; Cl, 30.37
Example 14 : 4.5 ' -N . N . N ' . N ' -Te t r ak i s ( 2 - chloroethyl) dianiline sulfoxide
With the use of 4, 4 '-N,N,N' ,N'-tetrakis (2- chloroethyl)dianiline sulfide (0.73 mmol, 0.35 g) prepared in Example 13, the procedure of Example 5 was repeated to give 0.31 g of the crude product as grey viscous oil. The crude oil was diluted in ethyl acetate (2 ml) and applied to three preparative TLC plates, and was then eluted with ethyl acetate / hexane (3:2). The regions with Rf = 0.35 were scraped, dissolved in ethyl acetate / ethanol (1:1), filtered and evaporated to give 220 mg (yield : 60.8%) of the product as a light grey solid.
TLC : Rf = 0.34 [hexane/ ethyl acetate (2:3)] 1H NMR (CDC13) δ (ppm) 6.41-6.90 & 7.29-7.67 [dd, 8H, S(C6H4)2], 3.55-4.02 [m, 16H, N(CH2CH2Cl)2] Elemental analysis C20H24C14N2SO
Calcd. : C, 49.81; H, 5.02; N, 5.81; S, 6.65; Cl, 29.40
Found : C, 49.83; H, 4.98; N, 5.77; S, 6.72; Cl, 29.34
Example 15 : 4.4'-N.N'-bis(2-hvdroxyethyl. dianiline sulfide 4,4'-Diaminodiphenyl sulfide (5.00 g, 23.1 mmol) prepared in Example 11 and 2-chloroethanol (6.2 ml, 7.44 g, 92.4 mmol) were added to a suspension of CaC03 (4.10 g, 41.0 mmol) in water (150 ml) . The cloudy mixture was heated under reflux, while being protected from light for 24 h. An additional 2 equivalents of 2-chloroethanol (3.1 ml, 3.72 g, 46.2 mmol) and CaC03 (4.62 g, 46.2 mmol) were added and the reaction mixture was heated under reflux for 24 h. The reaction mixture was then cooled, and the pH (4.2) was adjusted to 7.0 with 10% NaOH. The mixture was then extracted with ethyl acetate (4 x 100 ml) . The combined organic layer was dried over anhydrous sodium sulfate and evaporated to give 6.23 g of brown oil which contained 7 substances detected by UV after TLC operation. The crude oil was then applied to a silica gel column (40 μm, 5 x 15 cm) packed dry. Then it was wet and eluted with ethyl acetate / hexane (5:1) under a positive pressure (15 psi). The collected corresponding fractions were dried over anhydrous sodium sulfate and evaporated to obtain 0.77 g (yield: 11.0%) of the product as pale yellow oil. TLC : R = 0.23 (ethyl acetate / hexane = 4:1) 1H NMR (CDC13) <S (ppm)
6.37-6.70 & 6.92-7.31 [dd, 8H, S(C6H4)2], 3.76 [s, 2H, (NH-)2], 2.92-3.45 [m, 10H, N(CH2CH2OH)2]
Example 16 : 4.4'-NrN'-Bis(2-chloroethyl)dianiline sulfide With the use of 4,4'-N,N'-bis(2-hydroxyethyl)dianiline sulfide (21.4 mmol, 0.75 g) prepared in Example 15, the procedure of Example 12 was repeated to give 0.63 g of the crude product as golden yellow oil. The crude oil was diluted in ethyl acetate (3 ml) and applied to three preparative TLC plates, and was then eluted with ethyl acetate / hexane (1:3). The regions with Rf = 0.43 were scraped, dissolved in ethyl acetate / ethanol (1:1), filtered and evaporated to give 0.46 g (yield : 52.3%) of the product as a charcoal colored oil.
TLC : Rf = 0.43 [hexane/ ethyl acetate (3:1)], UV quenching and NBP positive 1H NMR (CDC13) δ (ppm)
6.51-6.89 & 7.04-7.41 [dd, 8H, S(C6H4)2], 3.96 [S, 2H, (NH-)2], 3.18-3.68 [m, 8H, N(CH2CH2C1)2]
Elemental analysis C16H18C1-N2S
Calcd. : C, 56.31; H, 5.32; N, 8.21; S, 9.39;
Cl, 20.78 Found : C, 56.22; H, 5.28; N, 8.14; S, 9.40; Cl, 20.81
Example 17 : 4.4 -N.N -Bis(2-chloroethyl.dianiline sulfoxide
With the use of 4,4'-N,N'-bis(2-chloroethyl)dianiline sulfide (0.91 mmol, 0.31 g) prepared in Example 16, 0.29 g of the crude product was obtained as light grey viscous oil. The crude oil was diluted in ethyl acetate (2 ml) and applied to three preparative TLC plates, and was then eluted with ethyl acetate / hexane (1:1). The regions with Rf = 0.35 were scraped, dissolved in ethyl acetate / ethanol (1:1), filtered and evaporated to give 0.23 g (yield : 70.1%) of the product as a white crystalline solid.
TLC : Rf = 0.35 [hexane/ ethyl acetate (1:1)] 1H NMR (CDC13) δ (ppm) 6.58-6.98 & 7.16-7.51 [dd, 8H, S(C6H4)2], 4.01 [s, 2H, (NH-)2], 3.22-3.75 [m, 8H, N(CH-CH2C1)2] Elemental analysis C16H18C12N2S0
Calcd. : C, 53.79; H, 5.08; N, 7.84; S, 8.97; Cl, 19.85
Found : C, 53.71; H, 4.97; N, 7.77; S, 8.95; Cl, 19.80
Example 18 : 4-[N.N-Bis(2-hydroxyethyl) 1amino-4 - nitrodiphenyl sulfide
To a solution of 4-amino-4'-nitrodiphenyl sulfide (25.00 g, 101.5 mmol) in 200 ml of THF and 250 ml of AcOH, 45 ml of 10% (w/v) of ethylene oxide in THF (102.2 mmol) was added at 5°C. The reaction mixture was stirred at room temperature for several days during which 45 ml of the ethylene oxide solution was added every day until mole ratio of ethylene oxide to the starting compound was about 7. The mixture was then neutralized with aqueous Na2C03, and extracted with ethyl acetate three times. The ethyl acetate extract was washed with water, dried over anhydrous sodium sulfate, and evaporated in vacuo to remove the solvent. The crude product was treated with charcoal in ethyl acetate solution to give 19.5 g of yellow product. The residue after evaporation of mother liquid was purified on a flash column using methylene chloride / acetone (8:2) as the eluant to obtain 7.8 g of the product. [Total yield : 80.43%] m.p. : 99.5 - 100.5 °C
TLC : Rf = 0.41 [methylene chloride / acetone (8:2)] 1H NMR (CDC13) δ (ppm)
6.63-8.03 (m, d, 8H, 02NC6H4SC6H4N) , 3.63-3.90 [d_, 8H, N(CH2CH2OH)2] Elemental analysis C16H18N204S
Calcd. : C, 57.47; H, 5.42; N, 8.38; S, 9.59 Found : C, 57.62; H, 5.51; N, 8.30; S, 9.48 Example 19 : 4-[N,N-Bis(2-chloroethyl) 1amino-4'- nitrodiphenyl sulfide
A mixture of 10.00 g (29.91 mmol) of 4-[N,N-bis(2- hydroxyethyl) ]amino-4'-nitrodiphenyl sulfide prepared in Example 18 and 65 ml of P0C13 was heated under reflux for 1 h, then the hot reaction mixture was poured to chopped ice with stirring. The resultant mixture was extracted with methylene chloride. The extract was treated with activated charcoal, washed with saturated aqueous sodium bicarbonate to pH 6 and washed with water, and dried over anhydrous
Na2S04, then evaporated in vacuo to give the crude product.
This crude product was purified with activated charcoal and crystallized with ethyl acetate / hexane to give 8.90 g of yellow product (yield: 80.15%).
m.p. : 112.5 - 113.5 °C
TLC : Rf = 0.51 [hexane / ethyl acetate (5:1)]
1H NMR (CDC13) δ (ppm)
6.63-8.06 (m, d, 8H, 0-NC6H4SC6H4N) , 3.73 [s, 8H, N(CH2CH2C1)2]
Elemental analysis C16H16N202C12S
Calcd. : C, 51.76; H, 4.34; N, 7.55; Cl , 19.10;
S, 8.64 Found : C, 51.87; H, 4.31; N, 7.59; Cl , 18.98; S, 8.69
Example 20 : 4 [N. N-Bis (2 -chloroethyl) laroino-4 '- nitrodiphenyl sulfoxide
To a solution of 4-[N,N-bis(2-chloroethyl) ]amino-4 '- nitrodiphenyl sulfide (13.50 g, 36.36 mmol) in trifluoroacetic acid (TFA, 64 ml) , 15.9 ml of H202 / TFA (36.36 mmol, prepared by mixing 4.3 ml of 30% H202 with 14.1 ml of TFA) was added while stirring at 5°C. The reaction was allowed to proceed for 6.5 h. After adding ethyl acetate and water, the reaction mixture was neutralized to pH 6-7 with aqueous sodium carbonate. The separated aqueous layer was extracted with ethyl acetate three times. Ethyl acetate extracts were combined and washed with water, dried over anhydrous sodium sulfate, and evaporated in vacuo. The crude product was crystallized with ethyl acetate / hexane to give 13.67 g (yield : 97.08%) of a yellow product. m.p. : 107 - 108 °C
TLC : Rf = 0.45 [hexane / ethyl acetate (1:1)] 1H NMR (CDC1-) δ (ppm)
6.63-8.40 (d, m, and d, 8H, 02NC6H4S0C6H4N) , 3.60-3.77 [t, 8H, N(CH2CH2C1)2] Elemental analysis C16H16N203C12S
Calcd. : C, 49.62; H, 4.16; N, 7.23; Cl, 18.31; S, 8.28
Found : C, 49.77; H, 4.19; N, 7.17; Cl, 18.30; S, 8.21
Example 21 : 4-fN.N-Bis(2-chloroethyl) 1amino-4 '- aminodiphenyl sulfoxide
Iron (19.14 g, 100 mesh) was activated by refluxing it with 1.5 ml of distilled water and 1 drop of concentrated hydrochloric acid for 0.5 h. Ethanol (68.4 ml) and 4 - [N,N - bis (2 - chloroethyl) amino - 4' - nitrodiphenyl sulfoxide (13.67 g, 35.30 mmol) prepared in Example 20 were added into the mixture at 40 - 50 °C. The reaction mixture was heated under reflux for 15 min. Several drops of 10% NaOH was added to the reaction mixture to pH 8. The hot reaction mixture was then filtered, and the residue was washed with ethanol and water. The filtrate was evaporated in vacuo to remove ethanol, and extracted with ethyl acetate three times. The ethyl acetate extract was dried over anhydrous sodium sulfate and evaporated in vacuo. The crude product was purified on a flash column using ethyl acetate / methylene chloride (6:4) as an eluant, and then recrystallized from ethyl acetate / hexane to give 9.09 g of off-white crystalline title compound (yield : 72.07%) and 0.8 g (6.64%) of off-white solid identified as 4-[N,N- bis (2-chloroethyl) ]amino-4 '-aminodiphenyl sulfide.
4- [N,N-bis( 2-chloroethyl) ]amino-4 '-aminodiphenyl sulfoxide m.p. : 136.5 - 138 °C TLC : Rf = 0.49 (ethyl acetate) H NMR (CDC13) δ (ppm) 6.60-7.50 (d, m, 8H, NC6H4S0C6H4N) , 3.60-3.73 [t,
8H, N(CH2CH2C1)2] Elemental analysis C16H18N20C12S
Calcd. : C, 53.79; H, 5.08; N, 7.84; Cl, 19.85; S, 8.97 Found : C, 53.88; H, 5.10; N, 7.89; Cl, 19.90;
S, 9.03
4- [N, N-Bis (2-chloroethyl) lamino-4 '-aminodiphenyl sulfide m.p. : 77 - 79 °C TLC : Rf = 0.64 [methylene chloride / acetone (196:4)]
1H NMR (CDC13) <_ (ppm)
6.50-7.30 (d, d, 8H, NC6H4SC6H4N) , 3.68 [s, 8H, N(CH2CH2C1)2] Elemental analysis C16H18N2C12S Calcd. : C, 56.13; H, 5.32; N, 8.21; Cl , 20.78;
S, 9.39 Found : C, 56.30; H, 5.33; N, 8.17; Cl , 20.68; S, 9.42
Example 22 : 4-N.N-Bis(chloroethyl)amino-4'-(9-acridinyl. aminodiphenyl sulfide hydrochloride
1) 9-Chloroacridine
A mixture of 5.00 g (5.12 mmol) of 9(10H)-acridone,
25.0 ml of S0C1-. and 0.1 ml of dimethylformamide was heated under reflux until a clear solution resulted and for additional 0.5 h. After removal of S0C12 in vacuo, the residue was dissolved in 70 ml of CHC13 and then stirred into chopped ice. Saturated aqueous NaHC03 was added to adjust the pH value to 7. The aqueous layer was extracted with CHC13. Then the combined CHC13 extract was washed with water, dried over anhydrous magnesium sulfate, and evaporated in vacuo. The residue was crystallized from CC14 to give 3.1 g (yield: 73.09%) of the product as greenish crystals. m.p. : 118.5 - 120.5 °C
TLC : Rf = 0.67 [methylene chloride / ethyl acetate
(92:8)] IR showed disappearance of the peak of C=0 and appearance of the peak of C-Cl.
2) 4- N,N-Bis (chloroethyl) amino-4 '- (9-acridinyl) aminodiphenyl sulfide hydrochloride
A solution of 4-[N,N-bis(2-chloroethyl) ]amino-4'- aminodiphenyl sulfide (0.52 g, 1.53 mmol) prepared in Example 21 and 9-chloroacridine (0.30 g, 1.40 mmol) prepared as above in N-methyl-2-pyrrolidinone (13.5 ml) was treated with a few drops of concentrated HCl and then stirred at room temperature for 1.5 h. The mixture was diluted with ethyl acetate, and the resultant precipitate was collected and washed with the same solvent to give a crude product. The crude product was mixed with 10 ml of
N-methyl-2-pyrrolidinone and the mixture stirred for 1 h.
Ethyl acetate (250 ml) was gradually added to complete the precipitation, and the resultant precipitate was collected and washed with ethyl acetate to give the pure title compound (0.70 g, yield: 89.4%) as reddish solid. m.p. : 261-262 °C
TLC : Rf=0 . 73 [ hexane/Et0Ac ( l : 1 ) ] 1H NMR ( CDC13 / DMS0-d6 1 : 4 ) <S (ppm) 6 . 70-8 . 40 (m , m , m , 16H , ArH) , 3 . 75 [ s , 8H , N(CH2CH2C1)2] Elemental analysis C29H26N3C13S
Calcd. : C, 62.76; H, 4.72; N, 7.57; Cl , 19.17; S, 5.78 Found : C, 62.83; H, 4.74; N, 7.48; Cl , 19.06;
S, 5.86
Example 23 : 4-ΓN.N-Bis(chloroethyl) ]amino-4'-(9-acridinyl) aminodiphenyl sulfoxide hydrochloride By the use of 4-[N,N-bis(2-chloroethyl) ]amino-4'- aminodiphenyl sulfoxide (1.00 g, 2.81 mmol) prepared in Example 21 and 9-chloroacridine (0.55 g, 2.57 mmol) prepared in Example 22, the procedure of Example 22 2) was repeated to give 1.3 g (yield: 88.45%) of the title compound as yellow solid, m.p. : 250-251 °C TLC : Rf = 0.81 (ethyl acetate) 1H NMR (CDC13 / DMS0-d6 1:4) 6 (ppm)
6.75-8.40 (m, m, m, 16H, ArH) , 3.75 [s, 8H, N(CH2CH2C1)2]
Elemental analysis C29H26N3Cl3OS
Calcd. : C, 61.01; H, 4.59; N, 7.36; Cl, 18.63;
S, 5.62 Found : C, 60.84; H, 4.86; N, 7.34; Cl , 18.47; S, 5.53
Experimental Example 1 : In Vitro Cytotoxicity Assessment A confluent flask of Chinese Hamster Lung V-79 transformed cells was scraped to collect the monolayer and the cells were counted by trypan blue dye exclusion. Glass milk dilution bottles were then inoculated with 500,000 cells in 10 ml of medium (minimum essential medium eagle supplemented with 10% fetal bovine serum, Penicilline G sodium, streptomycin sulfate, amphotericin and essential and non-essential amino acids and vitamins) and incubated for 20 hours in a 95% air/ 5% humidified atmosphere. One set of six bottles was sealed with sterilized rubber septa and fitted with 21-gauge needles for gas inflow and outflow. Each bottle was gassed individually, all outlet tubings and additive tubings immersed in water were connected to a flow meter (average flow velocity = 0.15 liter/min) to allow visible monitoring of gas flow as well as to prevent back flow of air into the cultures. To produce hypoxia, cultures were gassed continuously for 2h at 37°C with a humidified mixture of 95% N2 / 5% C02. Normally aerated cultures were maintained in air until drug treatment. At this time, appropriate dilutions of the drug in ethanol/water were added directly to the cultures, without breaking the hypoxia, by injecting 0.25 ml of drug through the rubber septa. In the aerobic set, cells were exposed to drug for 3h under normal aerated conditions. In hypoxic set, cells were gassed 10 min after injection of the drug, needles were pulled out and the sealed bottles were incubated for 3h in a normally aerated incubator. After drug exposure, the cells were washed twice with 5 ml sterile HBSS, and treated with 2.5% trypsin (Gibed® labs) for 2-3 min. Cells were collected by centrifugation, resuspended in 5 ml fresh solvent/or buffer and counted by trypan blue dye exclusion. Appropriate dilutions were made, and 500 cells were cultured in triplicate in a total of 10 ml medium. Dishes were incubated for 6-8 days to allow colony formation. Colonies were then rinsed twice with 0.9% saline, fixed with ethanol, stained with crystal violet and counted. Results were reported as the number of colonies surviving chemical treatment per number of colonies in the solvent treated control. The IC-0 values were determined by semi-logarithm plotting the drug concentration versus cell viability as determined by the number of colonies surviving the treatments. The results of the plotting with regard to the compounds prepared in the Examples are shown in Figs. 1 - 4. The IC50 and IC-0 values under normal or hypoxic condition are shown in Table 1 below.
Table 1
Figure imgf000029_0001
As can be shown from the above results, the sulfoxide derivatives according to the present invention have much lower cytotoxicity than the corresponding sulfide. It is found that the sulfoxides have rather higher cytotoxicity under hypoxic condition than under normal condition so that they have selective effects on a solid cancer having hypoxic condition as compared to the normal cells.
Experimental Example 2 : Tumor Inhibition in vivo
The B16 transformed cells cultured in vitro were treated with 0.25% trypsin, collected, washed with sterilized phosphate buffered saline (PBS) . And then the cell density was adjusted to 107 cells/ml. After 0.2 ml of cells (2 x 106 cells/ 0.2 ml/ mouse) were implanted into the subcutaneous tissue of the shoulder's upper part of BDF1 male mouse whose fur was previously eliminated, they were passaged in vivo per 14 days. B16 tumors were carefully isolated from the BDF1 male mouse tissue that had been passaged, necrosis cite was removed, and the weight of fresh tumor was measured. After adding sterilized physiological saline solution of 10-folds of the tumor weight, the mixture was ground by using a glass homogenizer to prepare a supernatant. The supernatant was transplanted to a subcutaneous tissue of the shoulder's upper part of BDF1 male mouse (0.2 ml/ mouse) (0th day). After 8 days, 45 animals having tumor tissue of 100 - 300 mm3 volume were selected and divided into the experimental groups at random (6 animals per each group) . The experimental compound(s) was administered into the abdominal cavity at the day 8 , 12, 16, and 20. As the experimental compound, 200 mg/kg of cyclophosphamide and 60 mg/kg of 2-hydroxypyrimidine were firstly administered into the abdominal cavity, and after 1 hr the compound according to the present invention(300, 150 mg/Kg) was administered. The tumor inhibition effect was evaluated by the body weight and the tumor growth inhibition rate (TGI) determined by the volumes of tumor in administered group and cotrol group at the day 8, 12, 16 and 20.
* Volume of tumor (mm3) = a x b x b x l/2 a : the longest diameter of the tumor b : the shortest diameter of the tumor
* TGI (Tumor Growth Inhibition rate, %) = (1 - Vt / Vc) x 100
Vt : tumor volume of the administered group (mm3) Vc : tumor volume of the vehicle control group (mm3)
The results of the plotting with regard to the compounds prepared in Examples are shown in Figs. 5 and 6. The change of body weight of the animals and tumor growth inhibition rate are shown in Tables 2 and 3 below.
Table 2 : Change of body weight of the BDF. mice transplanted with B16 tumor tissue
Figure imgf000031_0001
(* : PO.05, ** : PO.01 statistically significant CPM : cyclophosphamide) Table 3 : Results of tumor growth inhibition test in BDFi mice transplanted with B16 tumor tissue
Figure imgf000032_0001
(- ' P<0.05, ** • P<0.01 statistically significant CPM : cyclophosphamide)
As can be shown from the results, the growth of tumor can be inhibited by about 80% in case of administrating the sulfoxides of the present invention. The tumor inhibition effect rises by 10% when using the compound of the present invention with the conventional compounds as compared to the case using only cyclo phosphamide (70%) , which whows the inhibition of growth of the solid cancer transplanted to mice.

Claims

What is claimed is :
1. Sulfoxide derivatives of nitrogen-mustard represented by a general formula (I) and pharmaceutically acceptable salts thereof :
Figure imgf000034_0001
wherein, R1 represents a hydrogen, or haloethyl; R2 represents a lower alkyl or phenyl group substituted or non-substituted; and X represents a halogen atom, provided that R1 is a chloroethyl and X is a chlorine, R2 does not represent methyl group.
2 . Sulfoxide derivatives and salts thereof according to claim 1, wherein the compound is p-(n-propylεulfinyl)-N,N-bis(2-chloroethyl)aniline.
3. Sulfoxide derivatives and salts thereof according to claim 1, wherein the compound is p-(phenylsulfinyl)-N,N-bis (2-chloroethyl)aniline.
4. Sulfoxide derivatives and salts thereof according to claim 1, wherein the compound is 4,4'-N,N,N',N'-tetrakis(2-chloroethyl)dianiline sulfoxide.
5. Sulfoxide derivatives and salts thereof according to claim 1, wherein the compound is 4,4'-N,N'-bis(2-chloroethyl)dianiline sulfoxide.
6. Sulfoxide derivatives and salts thereof according to claim 1, wherein the compound is 4-[N,N-bis(chloroethyl)] amino-4'-(9-acridinyl) aminodiphenyl sulfoxide.
7. An anticancer agent comprising sulfoxide derivatives of nitrogen-mustard represented by a general formula (I) and pharmaceutically acceptable salts thereof as an active ingredient, with pharmaceutically acceptable carrier(s) :
Figure imgf000035_0001
wherein, R1 represents a hydrogen, or haloethyl; R2 represents a lower alkyl or phenyl group substituted or non-substituted; and X represents a halogen atom, provided that R1 is a chloroethyl and X is a chlorine, R2 does not represent methyl group.
PCT/KR1996/000173 1995-10-09 1996-10-09 Sulfoxide derivatives of nitrogen-mustard and anticancer agent containing the same Ceased WO1997013748A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU73406/96A AU7340696A (en) 1995-10-09 1996-10-09 Sulfoxide derivatives of nitrogen-mustard and anticancer agent containing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19950034486 1995-10-09
KR1995-34486 1995-10-09

Publications (1)

Publication Number Publication Date
WO1997013748A1 true WO1997013748A1 (en) 1997-04-17

Family

ID=19429582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR1996/000173 Ceased WO1997013748A1 (en) 1995-10-09 1996-10-09 Sulfoxide derivatives of nitrogen-mustard and anticancer agent containing the same

Country Status (3)

Country Link
KR (1) KR970020099A (en)
AU (1) AU7340696A (en)
WO (1) WO1997013748A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005793A1 (en) * 1999-07-19 2001-01-25 Pharmacia & Upjohn Company 1,2,3,4,5,6-HEXAHYDROAZEPINO[4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION
US7030109B2 (en) 1999-07-19 2006-04-18 Pharmacia & Upjohn Company 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 113, No. 25, 17 December 1990 (Columbus, Ohio, USA), page 704, Abstract No. 113:231187j, VALU, KISIONE K. et al., "DNA-Directed Alkylating Agents. 3. Structure-Activity Relationships for Acridine-Linked Aniline Mustards: Connsequences of Varying the Length of the Linker Chain"; & J. MED. CHEM., 1990, *
CHEMICAL ABSTRACTS, Vol. 114, No. 23, 10 june 1991 (Columbus, Ohio, USA), page 816, Abstract No. 114:228692k, GRAVATT, G. LANCE et al., "DNA-Directed Alkylating Agents. 4. 4-Anilinoquinoline-Based Minor Groove Directed Aniline Mustards"; & J. MED. CHEM., 1991, 34(5), 1552-60. *
CHEMICAL ABSTRACTS, Vol. 117, No. 5, 3 August 1992 (Columbus, Ohio, USA), page 32, Abstract No. 117:3991g, KWONG, CHUL HOON et al., "P-(Methyl= Sulfinyl)Phenyl Nitrogen Mustard as a Novel Bioreductive, Prodrug Selective Against Hypoxic Tumors"; & J. MED. CHEM., 1991, 35(11), 2137-9. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005793A1 (en) * 1999-07-19 2001-01-25 Pharmacia & Upjohn Company 1,2,3,4,5,6-HEXAHYDROAZEPINO[4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION
US6468999B1 (en) 1999-07-19 2002-10-22 Pharmacia & Upjohn Company 1,2,3,4,5,6,-hexahydroazepino [4,5-b]indoles containing arylsulfones at the 9-position
US6878823B2 (en) 1999-07-19 2005-04-12 Pharmacia & Upjohn Company 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
US6921823B2 (en) 1999-07-19 2005-07-26 Pharmacia & Upjohn Company Llc 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
US7030109B2 (en) 1999-07-19 2006-04-18 Pharmacia & Upjohn Company 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position

Also Published As

Publication number Publication date
KR970020099A (en) 1997-05-28
AU7340696A (en) 1997-04-30

Similar Documents

Publication Publication Date Title
JP2604783B2 (en) Bisnaphthalimide and a medicament containing the same that have tumor-suppressing and anti-leukemic effects
PT84896B (en) METHOD FOR THE PREPARATION OF DISTAMICINE ANALOGS WITH ANTINEOPLASTIC AND ANTI-VIRAL ACTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PT95584B (en) PREPARATION PROCESS OF ANTRAQUINONES, THEIR INTERMEDIARIES AND PHARMACEUTICAL COMPOSITIONS
RU2195452C2 (en) Cyanoguanidines, methods of their synthesis and pharmaceutical preparation based on thereof
US5530026A (en) Certain aryl-ureido anti-cancer agents
GB2203149A (en) 1-(6-amino-9-purinyl)- beta -D-ribofuranuronic acid amides and thioamides
AU598878B2 (en) Quinoline base compound, process for the preparation thereof and anticancer agent containing the same as pharmacologically efficacious component
SE469171B (en) 2-TIOXO-5-PYRIMIDINE CARBOXAMIDES, PHARMACEUTICAL COMPOSITION CONTAINING THESE, AND PROCEDURES FOR PREPARING THEREOF
EP0172744A2 (en) Phenazinecarboxamide compounds
EP0095355B1 (en) Substituted o-phenylenediamine compounds
EP0290558B1 (en) Antifolate agents
IE56782B1 (en) Substituted anthra(1,9-cd)pyrazol-6(2h)-ones
CN109053841B (en) 6-disulfur substituted-2&#39; -deoxyguanosine compound and preparation method and application thereof
RU2195451C2 (en) Cyanoguanidines, methods of their synthesis and pharmaceutical preparation based on thereof
US4071519A (en) 1-Carbamoyl-5-fluorouracil derivatives
WO1997013748A1 (en) Sulfoxide derivatives of nitrogen-mustard and anticancer agent containing the same
Giorgi-Renault et al. Heterocyclic quinones. XVII. A new in vivo active antineoplastic drug: 6, 7-bis (1-aziridinyl)-4-[[3-(N, N-dimethylamino) propyl] amino]-5, 8-quinazolinedione
EP0332190A2 (en) Condensed quinoline system compound, condensed acridine system compound, process for preparing the same, and carcinostatic composition containing the same
IE841617L (en) PYRAZOLO (3,4,5-kl) ACRIDINE
AU660883B2 (en) Anti-cancer anthracene derivative
CN108299415B (en) Quinolinequinone derivative and preparation method and application thereof
US11440916B2 (en) Selective A2A receptor antagonist
CZ282419B6 (en) BENZO(c)PHENANTHRIDINE DERIVATIVES, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
US4863935A (en) Mitomycin compounds having useful anti-tumor activity
RU2808534C1 (en) USE OF CYTOTOXIC AGENTS BASED ON SUBSTITUTED (E)-8-(2-OXO-2-R-ETHYLIDENE)-2-R1-3-R2-6-R3-PYRROLO[1,2-a]THIENO[3,2-e]PYRIMIDINE-4,7(5H,8H)-DIONES IN THE TREATMENT OF LUNG MELANOMA

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97514931

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA